Evidence map›Paper›PMID 26463014›Full record

ArticleActa biomaterialia2016

Fluorescence imaging enabled poly(lactide-co-glycolide).

Jianqing Hu, Jinshan Guo, Zhiwei Xie, Dingying Shan, Ethan Gerhard, Guoying Qian, Jian Yang

Abstract read
In one paragraph

Article in Acta biomaterialia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Development of Biodegradable Osteopromotive Citrate-Based Bone Putty.Small (Weinheim an der Bergstrasse, Germany) · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Citrate-Based Fluorescent Biomaterials.Advanced healthcare materials · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jianqing HuSchool of Chemistry and Chemical Engineering, South China University of Technology, Guangzhou 510640, China; Department of Biomedical Engineering, Materials Research Institute, The Huck Institutes of The Life Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
Jinshan GuoDepartment of Biomedical Engineering, Materials Research Institute, The Huck Institutes of The Life Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
Zhiwei XieDepartment of Biomedical Engineering, Materials Research Institute, The Huck Institutes of The Life Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
Dingying ShanDepartment of Biomedical Engineering, Materials Research Institute, The Huck Institutes of The Life Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
Ethan GerhardDepartment of Biomedical Engineering, Materials Research Institute, The Huck Institutes of The Life Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
Guoying QianZhejiang Provincial Top Key Discipline of Bioengineering, College of Biological and Environmental Sciences, Zhejiang Wanli University, Ningbo 315100, China.
Jian YangDepartment of Biomedical Engineering, Materials Research Institute, The Huck Institutes of The Life Sciences, The Pennsylvania State University, University Park, PA 16802, USA. Electronic address: jxy30@psu.edu.

Funding

Developing targeted therapy with prostate cancer specific nanomedicineR01CA182670 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HSIEH, JER-TSONG, YANG, JIAN · 2013 to 2017
$1.6M
Novel Engineered Particle Platform for Endothelium RegenerationR01HL118498 · NHLBI · UNIVERSITY OF TEXAS ARLINGTON · PI NGUYEN, KYTAI TRUONG, YANG, JIAN · 2014 to 2017
$1.5M
Creating Safe Biodegradable Photoluminescent Implant PolymersR01EB012575 · NIBIB · UNIVERSITY OF TEXAS ARLINGTON · PI YANG, JIAN · 2011 to 2014
$1.2M
NCI NIH HHS CA182670NCI NIH HHS R01 CA182670NHLBI NIH HHS HL118498NHLBI NIH HHS R01 HL118498NIBIB NIH HHS EB012575NIBIB NIH HHS R01 EB012575
6 · The paper itself

Abstract

Fluorescent biomaterials have attracted significant research efforts in the past decades. Herein, we report a new series of biodegradable, fluorescence imaging-enabled copolymers, biodegradable photoluminescent poly(lactide-co-glycolide) (BPLP-co-PLGA). Photoluminescence characterization shows that BPLP-co-PLGA solutions, films and nanoparticles all exhibit strong, tunable and stable photoluminescence. By adjusting the molar ratios of L-lactide (LA)/glycolide (GA) and (LA+GA)/BPLP, full degradation of BPLP-co-PLGA can be achieved in 8-16 weeks. The fluorescence decay behavior of BPLP-co-PLGA can be used for non-invasive monitoring of material degradation. In vitro cytotoxicity and in vivo foreign body response evaluations demonstrate that BPLP-co-PLGA exhibits similar biocompatibility to poly(lactide-co-glycolide) (PLGA). The imaging-enabled BPLP-co-PLGA was fabricated into porous scaffolds whose degradation can be monitored through non-invasive imaging and nanoparticles that show theranostic potential demonstrated by fluorescent cellular labeling, imaging and sustained 5-fluorouracil delivery. The development of inherently fluorescent PLGA copolymers is expected to impact the use of already widely accepted PLGA polymers for applications where fluorescent properties are highly desired but limited by the conventional use of cytotoxic quantum dots and photobleaching organic dyes. STATEMENT OF SIGNIFICANCE: This manuscript describes a novel strategy of conferring intrinsic photoluminescence to the widely used biodegradable polymers, poly(lactide-co-glycolide) without introducing any cytotoxic quantum dots or photo-bleaching organic dyes, which may greatly expand the applications of these polymers in where fluorescent properties are highly desired. Given the already significant impact generated by the use of PLGA and alike, this work contributes to fluorescence chemistry and new functional biomaterial design and will potentially generate significant impact on many fields of applications such as tissue engineering, molecular imaging and labeling, and drug delivery.

Indexed as

Fluorescent DyesMaterials TestingPolyglactin 910AnimalsFemaleHumansOptical ImagingRatsRats, Sprague-DawleyFluorescent DyesPolyglactin 910BiodegradableBioimagingDrug deliveryPhotoluminescencePLGATissue engineering

Identifiers

PMID26463014
PMCPMC4681614

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.